Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease.
Rory M C AbramsBrian D KimDesiree M MarkantoneKaitlin ReillyAlberto E Paniz-MondolfiMelissa R GitmanS Yoon ChooWinona TseJessica Robinson-PappPublished in: Journal of neurovirology (2020)
There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.
Keyphrases
- respiratory syndrome coronavirus
- coronavirus disease
- sars cov
- case report
- end stage renal disease
- risk factors
- drug induced
- newly diagnosed
- ejection fraction
- chronic kidney disease
- healthcare
- early onset
- multiple sclerosis
- risk assessment
- prognostic factors
- liver failure
- peritoneal dialysis
- intensive care unit
- acute respiratory distress syndrome
- replacement therapy
- smoking cessation